Claritas Pharmaceuticals, Inc.
CLAZF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.66K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3,659.00 |
|---|---|
| Enterprise Value | $549,659.00 |
| Earnings per Share | $0.16 |
| Beta | 2.12 |
| Outstanding Shares | 35,411,000 |
Return
| Return on Equity | -143.80% |
|---|---|
| Return on Assets | -42.80% |
| Return on Invested Capital | -112.73% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Next Earnings Call
Expected Date
November 30, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Claritas Pharmaceuticals, Inc.
3 employees
CEO: Robert Farrell
Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. ...